Compare NRIX & ETY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRIX | ETY |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2020 | 2005 |
| Metric | NRIX | ETY |
|---|---|---|
| Price | $26.16 | $14.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $30.50 | N/A |
| AVG Volume (30 Days) | ★ 976.1K | 256.3K |
| Earning Date | 04-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,987,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $8.20 | $13.12 |
| 52 Week High | $28.23 | $16.03 |
| Indicator | NRIX | ETY |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 53.57 |
| Support Level | $14.63 | $14.21 |
| Resistance Level | $28.23 | $14.78 |
| Average True Range (ATR) | 0.94 | 0.15 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 34.11 | 48.18 |
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.